 |
|
|
|
 |
egories |
 |
 |
New Addition |
 |
|
|
 |
Details: |
 |
|
|
Provides general information in a fact sheet format with access to articles, links, treatment options and clinical trials.
|
| URL: |
|
| Title: |
|
| Description: |
Health, Conditions and Diseases, Cancer, Brain and CNS - OnTumor: Brain Tumors. Provides general information in a fact sheet format with access to articles, links, treatment options and clinical trials. |
| Specialized in: |
|
|
 |
Popular Sites |
 |
 |
Related Press |
 |
Elekta Launches Web-based Virtual Clinic, Offers Better Understanding of Radiotherapy Solutions for the Treatment of Cancer (Popularity: ): Elekta, a world-class leader in advanced radiation therapy and radiosurgery, has created a three-dimensional virtual patient clinic, enabling clinicians, patients ...
Medical University of South Carolina Initiates New Trial of Cotara(R) in Brain Cancer Patients (Popularity: ): Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted antibodies for the treatment of cancer and hepatitis ...
Pharmacyclics Announces Encouraging Phase 2 Data With Xcytrin(R) in Recurrent Non-Small Cell Lung Cancer Patients (Popularity: ): Pharmacyclics, Inc. (Nasdaq: PCYC) today announced results from three open-label, multi-center Phase 2 clinical trials evaluating Xcytrin(R) (motexafin gadolinium) Injection, ...
Tumor Painting Revolutionizes Fight Against Cancer (Popularity: ): A tumor paint developed by researchers at Seattle Children's Hospital Research Institute and Fred Hutchinson Cancer Research Center will help ...
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients (Popularity: ): Dendreon Corporation (Nasdaq: DNDN) today announced publication of results from a Phase 1 study of NEUVENGE, an investigational active cellular ...
|
 |
Related Articles |
 |
|
|
 |
|
 |
| |
| | |
|
|
|
© 2003-2008, ABC-Directory.Com. All Rights Reserved
|
|
|
 |
|
 |
|